BICC1 and neoplasm: Intriguingly, the anti-tumour effect of gemcitabine could be improved by treating patient-derived xenograft models with elevated BICC1 expression with an anti-LCN2 antibody but not with the anti-VEGF antibody Bevacizumab [180].